Predicting Prostate Adenocarcinoma Patients’ Survival and Immune Signature: A Novel Risk Model Based on Telomere-Related Genes. Jief Zheng, Jiah Chen et al.

Published: 13 August 2023| Version 1 | DOI: 10.17632/xdnrtw7kpb.1
Jiahui Chen


Telomere-related genes (TRGs) play an essential role in the carcinogenesis and progression of prostate adenocarcinoma(PRAD). The prognostic value of TRGs remains unclear in PRAD. We conducted a study using The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) dataset as the training group and the Memorial Sloan-Kettering Cancer Center (MSKCC) and Gene Expression Omnibus (GEO) datasets as the validation group. We developed a risk model and a nomogram to predict survival rates in patients with PRAD. The expression of model genes and their possible regulatory mechanisms were then analyzed. Furthermore, we explored the relationship between the risk model and immune cell infiltration, chemotherapy drug sensitivity, and specific signaling pathways using the CIBERSORT algorithm, the Genomics of Drug Sensitivity in Cancer (GDSC) database, and motif enrichment. The integrated nomogram can be a good predictor of 3- and 5-year survival in patients with PRAD. This risk model is valuable for guiding the selection of immunotherapy and chemotherapy in the clinical treatment of patients with PRAD.



Prostate Cancer